Navigation Links
Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
Date:4/27/2009

WAYNE, Pa., April 27 /PRNewswire-FirstCall/ -- Encorium Group, Inc. (Nasdaq: ENCO), a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced that the Company was nominated for the Second Annual Vaccine Industry Excellence Award for Best Contract Research Organisation. Encorium was one of only seven leading CROs to be shortlisted for the award.

Dr. David Ginsberg, Encorium Group's Chief Executive Officer, stated, "We are thrilled and delighted to receive this significant recognition. It is an undisputable sign that our systematic pursuit of high quality in all aspects of our work is succeeding. I would like to express my gratitude to our outstanding teams, who have made this possible. Our sponsors can also rest assured that we will continue to focus on excellence in our operations."

Dr. Kai E. Lindevall, Executive Chairman of Encorium Group, stated, "It has been our explicit strategy to become one of the leading players in the field of prophylactic and therapeutic vaccines. This recognition of our achievements gives us confidence that it has been the right strategy. We will continue to further strengthen our capabilities in this field, as we strive to become the leading vaccine CRO globally."

In addition to Encorium, other companies shortlisted for the award include Quintiles, PPD, Icon Clinical Research, Covance, Accelovance and SNBL.

About Encorium Group, Inc.

Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industr
'/>"/>

SOURCE Encorium Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
2. Encorium Reports Third Quarter 2008 Financial Results
3. Encorium Announces Receipt of Letter from Nasdaq Regarding its Third Quarter 2008 Form 10-Q Filing
4. Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company
5. Encorium Group Signs Approximately $2.0 Million of New Business Contracts
6. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
7. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
8. Miaxis Biometrics Named as Red Herring 100 Asia Award Winner for 2007
9. Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
10. Hyaluron Contract Manufacturing Named a 2007 Economic Impact Award Finalist
11. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... As part of its philanthropic partnership ... Health Foundation funded a $3.25 million project to relocate ... the most up-to-date features and technology. , The new ... 45 staff members will begin moving from the current ... coming days. , The current pharmacy has been ...
(Date:5/21/2015)... Ontario (PRWEB) May 21, 2015 ... into an exclusive North American distribution agreement with ... testing system. , With more than 160 years ... products and services for laboratory and production facilities, ... operational excellence and differentiated services to enable science. ...
(Date:5/20/2015)... , May 20, 2015 Research and Markets ... of the "Top Technologies in HW_Technical Insights" ... of this report evaluated technology trends in the Health ... that are likely to have an impact in the ... analysis of the top 10 health and wellness technologies ...
(Date:5/20/2015)... 20, 2015  Select Medical Corporation ("Select") (NYSE: ... Commission granted early termination of the waiting period ... 1976, as amended, applicable to the acquisition of ... joint venture that Select has created with Welsh, ... previously announced, MJ Acquisition Corporation has signed a ...
Breaking Biology Technology:Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Top Technologies in the Health and Wellness Industry 2015 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... 12 Raptor Pharmaceuticals Corp.,(OTC Bulletin Board: RPTP), today ... clinical development subsidiary, will,present at the 2008 BIO International ... Diego Convention Center in San Diego, CA., Mr. ... 18, 2008 at 1:15p.m. (PT) in room 4 of ...
... MTA: CTIC) today announced that a single institutional investor,has ... Convertible,Senior Notes due 2011, with an initial conversion price ... 14.6 million shares of common stock,with an exercise price ... partial exercise of a previously granted,warrant right for the ...
... Organization Takes Prominent Position and ... WEST SENECA, N.Y., June 11 Palladian Muscular ... to,create a high-profile presence at a leading healthcare event ... Wednesday, June,18 to Friday, June 20, 2008., "We ...
Cached Biology Technology:Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention 2Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention 3Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention 4Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor 2Palladian Muscular Skeletal Health (formerly Prism Health Networks) to Promote Collaborative, Expanded Practice Model at Major Insurance Conference in June 2
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
(Date:5/6/2015)... TEL AVIV, Israel , May 6, 2015 /PRNewswire/ ... the world,s most established helmet producer, announced today that ... LifeBEAM Smart Helmet, the world,s first bio-sensing cycling helmet ... will be released in two new colors in order ... demand for the product. In addition, LifeBEAM and Lazer ...
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... of marine biologists has found that existing diversity in ... extreme temperature disturbances such as those predicted from ... on the species of algae living within corals may ... temperatures changes. The results will be published online in ...
... altitude medicine is a "natural research laboratory" for the ... can shed light on conditions and diseases that mimic ... top of mountains. Yves Allemann, MD, FESC, Swiss Cardiovascular ... Hospitalier Universitaire Vaudois, Lausanne, have assembled an international group ...
... Scientists at the University of Kentucky Markey Cancer Center ... enables tumor cells to spread to adjacent or distant parts ... opens the way to new lines of research aimed at ... by Peter Zhou, associate professor of molecular and cellular biochemistry ...
Cached Biology News:New study sheds light on corals' susceptibility to temperature change 2High-altitude research advances low-altitude medicine 2High-altitude research advances low-altitude medicine 3Key mechanism identified in metastatic breast cancer 2
... as an internal standard for the quantification ... spectrometry. 5-OxoETE is a polyunsaturated keto acid ... human neutrophils. It stimulates cytosolic calcium levels ... nM. 5-OxoETE selectively stimulates the migration and ...
... dsRNA Marker consists of ten double-stranded RNAs, ... 400, 500 and 1,000 base pairs. The ... for determinating sizes of double-stranded RNAs. A ... dsRNA Marker is adjusted to approximately 25 ...
... off-white solid. A nucleoside antibiotic that ... formation of N-glycosidic protein-carbohydrate linkages. Active ... bacteria, yeasts, fungi, and viruses. Inhibits ... on human T-lymphoblastoid cells. Also inhibits ...
... of enzymes involved in matrix degradation. Of ... ten exist in soluble form whereas MT-MMPs ... MT3-MMP also known as MMP14, MMP15, MMP16 ... them to the cell surface. They have ...
Biology Products: